These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 7845468)

  • 1. Catalytic specificity of protein-tyrosine kinases is critical for selective signalling.
    Songyang Z; Carraway KL; Eck MJ; Harrison SC; Feldman RA; Mohammadi M; Schlessinger J; Hubbard SR; Smith DP; Eng C
    Nature; 1995 Feb; 373(6514):536-9. PubMed ID: 7845468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The multiple endocrine neoplasia type 2B point mutation switches the specificity of the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck.
    Bocciardi R; Mograbi B; Pasini B; Borrello MG; Pierotti MA; Bourget I; Fischer S; Romeo G; Rossi B
    Oncogene; 1997 Nov; 15(19):2257-65. PubMed ID: 9393871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of Ret-Shc-Grb2 complex induced by GDNF, MEN 2A, and MEN 2B mutations.
    Ohiwa M; Murakami H; Iwashita T; Asai N; Iwata Y; Imai T; Funahashi H; Takagi H; Takahashi M
    Biochem Biophys Res Commun; 1997 Aug; 237(3):747-51. PubMed ID: 9299438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.
    Salvatore D; Melillo RM; Monaco C; Visconti R; Fenzi G; Vecchio G; Fusco A; Santoro M
    Cancer Res; 2001 Feb; 61(4):1426-31. PubMed ID: 11245446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Grb2 binding to the different isoforms of Ret tyrosine kinase.
    Alberti L; Borrello MG; Ghizzoni S; Torriti F; Rizzetti MG; Pierotti MA
    Oncogene; 1998 Sep; 17(9):1079-87. PubMed ID: 9764818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repair by Src kinase of function-impaired RET with multiple endocrine neoplasia type 2A mutation with substitutions of tyrosines in the COOH-terminal kinase domain for phenylalanine.
    Kato M; Takeda K; Kawamoto Y; Iwashita T; Akhand AA; Senga T; Yamamoto M; Sobue G; Hamaguchi M; Takahashi M; Nakashima I
    Cancer Res; 2002 Apr; 62(8):2414-22. PubMed ID: 11956105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RET alternate splicing influences the interaction of activated RET with the SH2 and PTB domains of Shc, and the SH2 domain of Grb2.
    Lorenzo MJ; Gish GD; Houghton C; Stonehouse TJ; Pawson T; Ponder BA; Smith DP
    Oncogene; 1997 Feb; 14(7):763-71. PubMed ID: 9047383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Catalytic specificity of phosphotyrosine kinases Blk, Lyn, c-Src and Syk as assessed by phage display.
    Schmitz R; Baumann G; Gram H
    J Mol Biol; 1996 Aug; 260(5):664-77. PubMed ID: 8709147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1.
    Kim DW; Hwang JH; Suh JM; Kim H; Song JH; Hwang ES; Hwang IY; Park KC; Chung HK; Kim JM; Park J; Hemmings BA; Shong M
    Mol Endocrinol; 2003 Jul; 17(7):1382-94. PubMed ID: 12738763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor.
    Plaza Menacho I; Koster R; van der Sloot AM; Quax WJ; Osinga J; van der Sluis T; Hollema H; Burzynski GM; Gimm O; Buys CH; Eggen BJ; Hofstra RM
    Cancer Res; 2005 Mar; 65(5):1729-37. PubMed ID: 15753368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by ret with the MEN 2B mutation.
    Murakami H; Iwashita T; Asai N; Shimono Y; Iwata Y; Kawai K; Takahashi M
    Biochem Biophys Res Commun; 1999 Aug; 262(1):68-75. PubMed ID: 10448070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B.
    Carlson KM; Dou S; Chi D; Scavarda N; Toshima K; Jackson CE; Wells SA; Goodfellow PJ; Donis-Keller H
    Proc Natl Acad Sci U S A; 1994 Feb; 91(4):1579-83. PubMed ID: 7906417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recognition of a high-affinity phosphotyrosyl peptide by the Src homology-2 domain of p56lck.
    Eck MJ; Shoelson SE; Harrison SC
    Nature; 1993 Mar; 362(6415):87-91. PubMed ID: 7680435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease.
    Carlomagno F; Melillo RM; Visconti R; Salvatore G; De Vita G; Lupoli G; Yu Y; Jing S; Vecchio G; Fusco A; Santoro M
    Endocrinology; 1998 Aug; 139(8):3613-9. PubMed ID: 9681515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A mutation in the RET proto-oncogene in Hirschsprung's disease affects the tyrosine kinase activity associated with multiple endocrine neoplasia type 2A and 2B.
    Cosma MP; Panariello L; Quadro L; Dathan NA; Fattoruso O; Colantuoni V
    Biochem J; 1996 Mar; 314 ( Pt 2)(Pt 2):397-400. PubMed ID: 8670046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the Ron receptor.
    Santoro MM; Penengo L; Minetto M; Orecchia S; Cilli M; Gaudino G
    Oncogene; 1998 Aug; 17(6):741-9. PubMed ID: 9715276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ret-mediated mitogenesis requires Src kinase activity.
    Melillo RM; Barone MV; Lupoli G; Cirafici AM; Carlomagno F; Visconti R; Matoskova B; Di Fiore PP; Vecchio G; Fusco A; Santoro M
    Cancer Res; 1999 Mar; 59(5):1120-6. PubMed ID: 10070972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of SNT/FRS2 docking site on RET receptor tyrosine kinase and its role for signal transduction.
    Kurokawa K; Iwashita T; Murakami H; Hayashi H; Kawai K; Takahashi M
    Oncogene; 2001 Apr; 20(16):1929-38. PubMed ID: 11360177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A remote substrate docking mechanism for the tec family tyrosine kinases.
    Joseph RE; Min L; Xu R; Musselman ED; Andreotti AH
    Biochemistry; 2007 May; 46(18):5595-603. PubMed ID: 17439160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Shc docking site on Ret tyrosine kinase.
    Arighi E; Alberti L; Torriti F; Ghizzoni S; Rizzetti MG; Pelicci G; Pasini B; Bongarzone I; Piutti C; Pierotti MA; Borrello MG
    Oncogene; 1997 Feb; 14(7):773-82. PubMed ID: 9047384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.